SLIDE 1
www.escardio.org/guidelines
2016 ESC Guidelines for the Diagnosis and Treatment of
- n Acute & Chronic
2016 ESC Guidelines for the Diagnosis and Treatment of on Acute - - PowerPoint PPT Presentation
2016 ESC Guidelines for the Diagnosis and Treatment of on Acute - - PowerPoint PPT Presentation
2016 ESC Guidelines for the Diagnosis and Treatment of on Acute & Chronic Heart Failure The importance of Stefan D. Anker, MD, PhD Gttingen / Germany Co-morbidities www.escardio.org/guidelines Co-morbidities to consider in HF &
SLIDE 2
SLIDE 3
www.escardio.org/guidelines
Co-morbidities to consider in HF & important studies
- CAD / ischemia & Hypertension
- Diabetes mellitus & Metabolic syndrome
- Sleep apnoea
- Depression & Stroke
- Anemia and iron deficiency
- Renal dysfunction and kidney injury
- COPD
- Liver & bowel dysfunction
- Cachexia & muscle wasting
SLIDE 4
www.escardio.org/guidelines
Co-morbidities to consider in HF & important studies
- CAD / ischemia & Hypertension
- Diabetes mellitus & Metabolic syndrome
- Sleep apnoea
- Depression & Stroke
- Anemia and iron deficiency
- Renal dysfunction and kidney injury
- COPD
- Liver & bowel dysfunction
- Cachexia & muscle wasting
consider empagliflozin EMPA-REG-Outcome consider Hyperkalaemia (Patiromer, ZS-9) consider CONFIRM-HF consider SERVE-HF
SLIDE 5
www.escardio.org/guidelines
Importance of co-morbidities in patients with HF
SLIDE 6
www.escardio.org/guidelines
Recommendations for the prevention of thrombo-embolism in patients with symptomatic HF (NYHA II–IV) & paroxysmal or persistent/permanent AF
SLIDE 7
www.escardio.org/guidelines
Treatment of stable angina pectoris with symptomatic HF (NYHA II-IV) with reduced ejection fraction
SLIDE 8
www.escardio.org/guidelines
Recommendations for the treatment of hypertension in patients with symptomatic HF (NYHA II-IV) with reduced ejection fraction
SLIDE 9
www.escardio.org/guidelines
Recommendations for the treatment of other co-morbidities in patients with HF
=> should be treatment of choice, except in severe renal or hepatic impairment
SLIDE 10
www.escardio.org/guidelines
Statements on empagliflozin in the 2016 HF GL 11.6 Diabetes
“Recently, empagliflozin, an inhibitor of sodium-glucose cotransporter 2, reduced hospitalization for HF and mortality, but not myocardial infarction or stroke, in patients with diabetes at high cardiovascular risk, some of whom had HF.130 In the absence of other studies with drugs from this group, the results obtained with empaglifozin cannot be considered as a proof of a class effect.“
(page 37 of 85)
SLIDE 11
www.escardio.org/guidelines
Treatments not recommended of other co-morbidities in patients with heart failure
SLIDE 12
www.escardio.org/guidelines
Recommendations for treatment of valvular diseases in patients with heart failure
SLIDE 13
www.escardio.org/guidelines
Causes of elevated concentrations of natriuretic peptides
SLIDE 14
www.escardio.org/guidelines
Characteristics and components of management programmes for patients with HF
SLIDE 15
www.escardio.org/guidelines
Recommendations for exercise, multidisciplinary management and monitoring of patients with HF
SLIDE 16
www.escardio.org/guidelines
Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (1)
SLIDE 17
www.escardio.org/guidelines
Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (2)
SLIDE 18
www.escardio.org/guidelines
Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (3)
SLIDE 19
www.escardio.org/guidelines
Specific recommendations regarding monitoring & follow-up of older adults with HF
SLIDE 20
www.escardio.org/guidelines
Patients with heart failure in whom end of life care should be considered
SLIDE 21
www.escardio.org/guidelines
Key components of palliative care service in patients with heart failure
SLIDE 22
www.escardio.org/guidelines
Co-morbidities to consider in HF – gaps of knowledge
- CAD / ischemia & Hypertension
- Diabetes mellitus & Metabolic syndrome
- Sleep apnoea
- Depression & Stroke
- Anemia and iron deficiency
- Renal dysfunction and kidney injury
- COPD
- Liver & bowel dysfunction
- Cachexia & muscle wasting
SLIDE 23
www.escardio.org/guidelines
Ponikowski P, et al. Eur J Heart Fail 2016 & EHJ 2016 (online available)